Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2016-10-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2016.07.031PMID 27543389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: Structure-activity relationship and a pharmacophore model.

  2016cited by this paper
• Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A.

  2015cited by this paper
• Recent developments with metalloprotease inhibitor class of drug candidates for botulinum neurotoxins.

  2015cited by this paper
• DOCK 6: Impact of new features and current docking performance

  2015cited by this paper
• Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation.

  2015cited by this paper
• Pharmacophore-Based Similarity Scoring for DOCK

  2014cited by this paper
• Strategies for lead discovery: application of footprint similarity targeting HIVgp41.

  2014cited by this paper
• Botulinum neurotoxins: genetic, structural and mechanistic insights

  2014cited by this paper
• Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia

  2014cited by this paper
• Differential role of molten globule and protein folding in distinguishing unique features of botulinum neurotoxin.

  2014cited by this paper
• Second Generation Steroidal 4-Aminoquinolines Are Potent, Dual-Target Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease and P. falciparum Malaria

  2014cited by this paper
• Identification of Clinically Viable Quinolinol Inhibitors of Botulinum Neurotoxin A Light Chain

  2014cited by this paper
• PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.

  2013cited by this paper
• Grid‐based molecular footprint comparison method for docking and de novo design: Application to HIVgp41

  2013cited by this paper
• Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.

  2012cited by this paper
• Discovery of a fluorene class of compounds as inhibitors of botulinum neurotoxin serotype E by virtual screening.

  2012cited by this paper
• A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.

  2012cited by this paper
• Footprint-based identification of viral entry inhibitors targeting HIVgp41.

  2012cited by this paper
• Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs

  2012cited by this paper
• Evaluation of DOCK 6 as a pose generation and database enrichment tool

  2012cited by this paper
• ZINC: A Free Tool to Discover Chemistry for Biology

  2012cited by this paper
• Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility.

  2011cited by this paper
• Implementation and evaluation of a docking‐rescoring method using molecular footprint comparisons

  2011cited by this paper
• Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors.

  2010cited by this paper
• Efficacy of a Potential Trivalent Vaccine Based on Hc Fragments of Botulinum Toxins A, B, and E Produced in a Cell-Free Expression System

  2010cited by this paper
• Docking Validation Resources: Protein Family and Ligand Flexibility Experiments

  2010cited by this paper
• Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.

  2010cited by this paper
• Origins of resistance to the HIVgp41 viral entry inhibitor T20.

  2010cited by this paper
• Progress and challenges

  2009cited by this paper
• Quantitative prediction of fold resistance for inhibitors of EGFR.

  2009cited by this paper
• Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.

  2008cited by this paper
• SNAP-25 Substrate Peptide (Residues 180–183) Binds to but Bypasses Cleavage by Catalytically Active Clostridium botulinum Neurotoxin E*

  2008cited by this paper
• Structure- and Substrate-based Inhibitor Design for Clostridium botulinum Neurotoxin Serotype A*

  2008cited by this paper
• The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.

  2008cited by this paper
• A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease.

  2007cited by this paper
• Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

  2007cited by this paper
• Use of a Recombinant Fluorescent Substrate with Cleavage Sites for All Botulinum Neurotoxins in High-Throughput Screening of Natural Product Extracts for Inhibitors of Serotypes A, B, and E

  2007cited by this paper
• Trivalent Vaccine against Botulinum Toxin Serotypes A, B, and E That Can Be Administered by the Mucosal Route

  2007cited by this paper
• Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

  2006cited by this paper
• Unique Substrate Recognition by Botulinum Neurotoxins Serotypes A and E*

  2006cited by this paper
• Comparison of multiple Amber force fields and development of improved protein backbone parameters

  2006cited by this paper
• Development and testing of a general amber force field

  2004cited by this paper
• A high‐affinity competitive inhibitor of type A botulinum neurotoxin protease activity

  2002cited by this paper
• Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation

  2002cited by this paper
• Botulinum toxin as a biological weapon: medical and public health management.

  2001cited by this paper
• Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models.

  2000cited by this paper
• Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method

  2000cited by this paper
• Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices

  1998cited by this paper
• Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1′ binding subsite

  1998cited by this paper
• Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate

  1998cited by this paper
• Use of Structure-Activity Data To Compare Structure-Based Clustering Methods and Descriptors for Use in Compound Selection

  1996cited by this paper
• The high‐affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a

  1996cited by this paper
• Mechanism of action of tetanus and botulinum neurotoxins

  1994cited by this paper
• Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

  1992cited by this paper
• Automated docking with grid‐based energy evaluation

  1992cited by this paper
• Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure.

  1988cited by this paper
• Comparison of simple potential functions for simulating liquid water

  1983cited by this paper

• Targeting the Enzymatic Site of Botulinum Neurotoxin Type E With 8‐Hydroxyquinolinol–Based Inhibitors: In Silico, In Vitro, and In Vivo Evaluation

  2025cites this paper
• Mutations in Mig6 reduce inhibition of the epidermal growth factor receptor

  2024cites this paper
• Neutral ceramidase-active site inhibitor chemotypes and binding modes.

  2023cites this paper
• Fragment-Based Lead Discovery Strategies in Antimicrobial Drug Discovery

  2023cites this paper
• A molecular evolution algorithm for ligand design in DOCK

  2022cites this paper
• Identification of Zika Virus Inhibitors Using Homology Modeling and Similarity-Based Screening to Target Glycoprotein E

  2020cites this paper
• Free Energy Landscapes for RBD Opening in SARS-CoV-2 Spike Glycoprotein Simulations Suggest Key Interactions and a Potentially Druggable Allosteric Pocket

  2020cites this paper
• Insights into an alternative benzofuran binding mode and novel scaffolds of polyketide synthase 13 inhibitors

  2019cites this paper
• Identification of Fatty Acid Binding Protein 5 Inhibitors Through Similarity-Based Screening

  2019cites this paper
• Targeted 8-hydroxyquinoline fragment based small molecule drug discovery against neglected botulinum neurotoxin type F.

  2019cites this paper
• Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry

  2019cites this paper
• High level expression and immunochemical characterization of botulinum neurotoxin type F light chain.

  2018cites this paper
• Identification of a Water-Coordinating HER2 Inhibitor by Virtual Screening Using Similarity-Based Scoring

  2018cites this paper
• The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites.

  2017cites this paper
• Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets

  2017cites this paper